Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C13H18N2 |
| Molecular Weight | 202.2954 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CN2CCC1CCC2C3=CN=CC=C3
InChI
InChIKey=WIEWCOLOPGXZDJ-UHFFFAOYSA-N
InChI=1S/C13H18N2/c1-2-12(10-14-7-1)13-4-3-11-5-8-15(13)9-6-11/h1-2,7,10-11,13H,3-6,8-9H2
| Molecular Formula | C13H18N2 |
| Molecular Weight | 202.2954 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P36544 Gene ID: 1139|||89832 Gene Symbol: CHRNA7 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/14722323 |
440.0 nM [EC50] |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:41:21 GMT 2025
by
admin
on
Wed Apr 02 08:41:21 GMT 2025
|
| Record UNII |
NF9LS47A5E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
TC-1698
Created by
admin on Wed Apr 02 08:41:21 GMT 2025 , Edited by admin on Wed Apr 02 08:41:21 GMT 2025
|
PRIMARY | |||
|
700834-58-8
Created by
admin on Wed Apr 02 08:41:21 GMT 2025 , Edited by admin on Wed Apr 02 08:41:21 GMT 2025
|
PRIMARY | |||
|
NF9LS47A5E
Created by
admin on Wed Apr 02 08:41:21 GMT 2025 , Edited by admin on Wed Apr 02 08:41:21 GMT 2025
|
PRIMARY | |||
|
DTXSID40435998
Created by
admin on Wed Apr 02 08:41:21 GMT 2025 , Edited by admin on Wed Apr 02 08:41:21 GMT 2025
|
PRIMARY | |||
|
10130417
Created by
admin on Wed Apr 02 08:41:21 GMT 2025 , Edited by admin on Wed Apr 02 08:41:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->PARTIAL AGONIST |
|